Skip to main content
ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. logo

ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. — Investor Relations & Filings

Ticker · 300009 ISIN · CNE100000GY2 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,016 across all filing types
Latest filing 2020-04-07 Report Publication Anno…
Country CN China
Listing Shenzhen Stock Exchange 300009

About ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD.

https://www.ankebio.com

Anhui Anke Biotechnology (Group) Co., Ltd. is a high-tech enterprise specializing in the research, development, production, and commercialization of biopharmaceutical products. The company focuses on genetic engineering, cell therapy, and precision medicine. Its core product portfolio includes recombinant human growth hormone (rhGH) marketed under the brand Ansomone, and recombinant human interferon alpha-2b known as Anterferon. Anke Bio also develops diagnostic reagents, including biochemical and molecular diagnostic kits, and provides services in the fields of oncology and reproductive health. The company maintains a strong emphasis on innovation through its dedicated R&D centers, aiming to provide advanced therapeutic solutions for growth disorders, viral infections, and various cancers. Its operations span the entire value chain from basic research to clinical application and market distribution.

Recent filings

Filing Released Lang Actions
2019年年度报告提示性公告
Report Publication Announcement Classification · 100% confidence The document is a short announcement (343 characters) titled '2019 Annual Report Reminder Announcement' from Anhui Anke Biotechnology Engineering (Group) Co., Ltd. It states that the 2019 annual report and summary have been disclosed on the designated information disclosure website and advises investors to check it. The document does not contain the actual annual report or financial data but merely announces its availability. According to the 'MENU VS MEAL' rule, such a brief notice that points to the report being published elsewhere should be classified as a Report Publication Announcement (RPA), not as the Annual Report (10-K) itself.
2020-04-07 Chinese
关于安徽安科余良卿药业有限公司受让控股子公司部分股权暨关联交易的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding a related party transaction involving the transfer of equity in a subsidiary company. It details the transaction overview, parties involved, financial data of the target company, pricing policy, transaction terms, and approvals by the board and independent directors. There is no indication that this is a full financial report, audit report, or earnings release. It is a regulatory announcement about a capital transaction involving shareholding changes within subsidiaries and related parties. The document is not a report publication announcement or certification. The content fits best under Capital/Financing Update (CAP) as it concerns a financing-related transaction and equity transfer within the corporate group.
2020-04-07 Chinese
关于变更部分募集资金专项账户的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Anhui Anke Biotechnology Engineering (Group) Co., Ltd. regarding the change of certain special accounts for raised funds. It details the board and supervisory committee meetings approving the change, the background of the fundraising, the amounts involved, and the management of the raised funds accounts. The document does not contain financial statements or detailed financial performance data but focuses on the management and transfer of fundraising accounts. It is a regulatory announcement about the company's capital management and fundraising account changes, not a full financial report or earnings release. The document length is about 4207 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2020-04-07 Chinese
募集资金年度存放与使用情况鉴证报告
Audit Report / Information Classification · 95% confidence The document is titled '募集资金年度存放与使用情况 鉴证报告' which translates to 'Annual Verification Report on the Storage and Use of Raised Funds'. It is issued by an accounting firm (容诚会计师事务所) and addresses the company's raised funds management and usage for the year 2019. The document references regulatory guidelines from the China Securities Regulatory Commission and Shenzhen Stock Exchange regarding the management and disclosure of raised funds. It includes detailed financial data on the amount raised, usage, balances, and compliance with regulations. This type of report is a specialized audit or assurance report on the use of capital raised by the company, distinct from a full annual report or earnings release. It fits the definition of an Audit Report / Information (AR) as it is a standalone audit/verification report on a specific financial aspect (raised funds usage) and not a full annual report or interim report. The document length (5540 characters) and content confirm it is the report itself, not just an announcement or certification letter. Therefore, the appropriate classification is AR with high confidence. FY 2019
2020-04-07 Chinese
关于募集资金年度存放与使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "募集资金年度存放与使用情况专项报告" which translates to "Annual Report on the Storage and Use of Raised Funds." It details the amount of funds raised through a non-public issuance, the timing of fund receipt, the usage and balance of the raised funds, and compliance with regulatory requirements. It references regulatory guidelines from the Shenzhen Stock Exchange and the China Securities Regulatory Commission. The document includes detailed financial figures on the raised funds, their allocation, and bank account balances. It is a specialized report focused on the management and use of capital raised by the company, not a general annual report or earnings release. This type of document corresponds to a Capital/Financing Update (CAP) as it provides updates on fundraising and the use of capital raised. The document length is under 5,000 characters but contains substantive financial data and detailed usage information, so it is not merely an announcement or a report publication notice. Therefore, the correct classification is CAP with high confidence.
2020-04-07 Chinese
并购上海苏豪逸明制药有限公司形成的商誉进行减值测试涉及的预计未来现金流量现值评估项目资产评估报告
Audit Report / Information Classification · 95% confidence The document is titled as an "资产评估报告" (Asset Evaluation Report) related to the impairment test of goodwill formed by the acquisition of Shanghai Suhao Yiming Pharmaceutical Co., Ltd. by Anhui Anke Bioengineering (Group) Co., Ltd. It contains detailed valuation methodology, legal and accounting standards references, asset and liability breakdowns, and financial data used for the impairment test. The report is prepared by an asset evaluation company and is comprehensive, exceeding 15,000 characters, indicating it is the full report rather than an announcement or summary. The content focuses on valuation and impairment testing rather than audit opinions or financial statement certifications, so it is not an Audit Report (AR). It is not an Annual Report (10-K) or Interim Report (IR) as it is a specialized valuation report. It is not a regulatory filing or announcement. The document fits best into the category of Audit Report / Information (AR) as it is a standalone valuation report related to impairment testing, which is a type of audit-related information but not a full annual report. Therefore, the classification is AR with high confidence. FY 2019
2020-04-07 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.